PLUS THERAPEUTICS, INC.

Analysis for Ticker: PSTV

Plus Therapeutics, Inc operates as a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for rare and complex central nervous system tumors using a hybrid-virtual model. Its primary candidate is REYOBIQ, an injectable radiation treatment for brain cancer, but the mathematical reality of the business is far more toxic than the disease. This entity has managed to spend over 515$ million while generating zero commercial revenue. Imagine a bakery that borrows money to bake bread but the bakers eat every loaf while charging the neighbors for the privilege of watching the oven burn. Their net equity burn rate exploded to 17,9% in 2025 while total dilution reached 10,3%. By 02/04/2026 the company was forced to shrink 171,5 million shares into a mere 6,8 million through a reverse stock split just to keep its ticker from being removed from the exchange. It is not a functioning business; it is a financial vacuum designed to move public money into executive pockets before the treasury hits zero.